Vaxneuvance - direct healthcare professional communication (DHPC)

Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)

Über

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Dokumente

Direct healthcare professional communication (DHPC): Vaxneuvance (pneumococcal polysaccharide conjugate vaccine) suspension for injection: Important information regarding the potential for breakage of Vaxneuvance pre-filled syringes

Key facts

• Medicine name:
  Vaxneuvance
• Active substance:
  Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)
• Therapeutic area (MeSH):
  Pneumococcal Infections
• Regulatory outcome:
  Maintenance
• DHPC type:
  Quality defect
• Human ATC codes:
  J07AL02
• Dissemination date:
  20/09/2023